A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

NCT02203513 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

111

Enrollment

NIH

Sponsor class

Stopped Eli Lilly prematurely terminated the study.

Conditions

Ovarian Cancer
Breast Cancer
Prostate Cancer

Interventions

DRUG: LY2606368

Sponsor

National Cancer Institute (NCI)